Two new DTPA analogues, centrally (L 
Introduction
Diethylenetriaminepentaacetic acid (DTPA) is one of the most well-known ligands and yields highly stable complexes with hard metal ions. DTPA and its derivatives have been used in a vast array of applications of medical interest, such as contrast agents for medical imaging, [1] [2] [3] [4] [5] radiotherapy, radiolabeling of antibodies and peptides, 6-9 radiopharmaceuticals and chelation therapy. [10] [11] [12] In particular, the gadolinium complex of DTPA has long been successful as a contrast agent, ever since it was approved by the FDA in 1988. 13 However, the perceived disadvantage of Gd-DTPA is that the chelate has been prepared in hypertonic solutions, where issues related to high osmolarity become signicant. The investigations have been intensied on the synthesis and characteristics of novel Gd(III) complexes to minimize toxicity issues while ensuring relaxation rate enhancement. The biocompatibility of the multidentate DTPA derivatives makes it an ideal choice. DTPA also offers the advantage of incorporating a well-dened structural molecule, to a chosen biological molecule (which could be proteins in the blood, antibodies or similar biological macromolecules) due to their multidentate feature.
Several strategies have been utilised in the synthesis of substituted DTPA frameworks. These approaches include (i) the attachment of substituents via an amide linkage to a carboxylate group of the preformed DTPA ligand or (ii) the direct bonding of the substituent to the diethyltriamine core.
The attachment of substituents to DTPA via an amide link is a useful strategy as it is a simple and convenient method that can give compounds in high yields and good purity. There are numerous reported methods to carry this reaction out.
14-25 Some methods involve the use of coupling reagents to couple the amine containing substituent to the DTPA, 26 though the simplest method involves the conversion of DTPA to the bisanhydride analogue, which may then be directly reacted with a suitable amine. [27] [28] [29] While this is an extremely effective approach, the method has some drawbacks in that, despite reports of the synthesis on mono substituted analogues, 30 such reactions are difficult and oen an impure product is obtained which requires extensive efforts to purify. Secondly, the substituent is bound by an amide group which results in a lower thermodynamic stability and potentially increased toxicity.
For the direct attachment of a moiety to the diethyltriamine framework, typically, (i) a single moiety may be attached to the central nitrogen, 31 (ii) two identical moieties may be attached to the terminal nitrogens 32, 33 or (iii) the ethylene spacers of the framework may be substituted.
34,35
The dialkylation of a primary amine using di-tert-butyl 2,2 0 -((2-bromoethyl)azanediyl)diacetate (2) will result in the formation of a DTPA framework. Amino acids, such as L-cysteine,
36
L-phenylalanine, 37 L-glutamic acid and lysine, 38 were previously utilised as primary amines in the construction of such DTPA analogues. In addition, there is a further report of an aliphatic alkyl amine 31 being used as the central moiety of a constructed DTPA-like ligand.
Further, bi-substituted DTPA analogues have been constructed from diethylene triamine starting material using two equivalents of 2,2 0 -bipyridine-5-carboxaldehyde, 32 while Artali et al. 33 reported an analogous approach to incorporate the 2-hydroxymethyl pyridine group. However, it should be noted, that reports of mono substituted terminal nitrogens of a DTPA frame-work are scarce.
39-42
Furthermore, reproducible relaxivity measurements reported for L 1 in this report is on the higher side. 
DTPA based amide derivatives bearing chromophores: a novel approach
Herein we report the synthesis of two potential dual mode imaging agents. The synthesised ligand will contain a single organic luminescent moiety which has been directly alkylated to the nitrogen atom of a diethylene triamine. Two possibilities exist, with the lumophore being alkylated to the central nitrogen or to one of the two terminal nitrogens. The rst approach utilises 2 for the dialkylation of the appropriate amine. This approach will produce a symmetric ligand (Fig. 2, type A) . The appropriate choice of amine will yield a ligand with a lumophore bonded to the central amine. The second approach utilises a monosubstituted diethylene triamine species which may be alkylated to yield an asymmetrically monosubstituted DTPA ligand (type B). The lumophore is incorporated into these ligand frameworks as the naphthalimide moiety (Fig. 2) .
Experimental

General experimental
Reagents were obtained from commercial sources and used as received unless otherwise noted. Solvents were dried and puried under N 2 by using standard methods and were distilled immediately before use, specically dimethlyformamide, was distilled using anhydrous calcium hydride. All compounds were prepared under N 2 unless otherwise mentioned. The NMR spectra were obtained using a Bruker ARX 400 at 20 C in CDCl 3 unless otherwise noted. Mass spectra were performed on a micromass platform II system, operating in ow injection analysis mode, with the electrospray method. Infrared spectra were recorded with a JASCO FTIR-410 spectrometer, between 4000 and 500 cm À1 as KBr pellets. UV/vis spectra and measurements were recorded with a JASCO V-570 spectrophotometer.
The synthesis of 2-(2-aminoethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (3) was carried out following the reported literature procedure. 
Luminescence measurements
The photophysical data for luminescence were obtained on a JobinYvon-Horiba Fluorolog spectrometer tted with a JYTBX picosecond photo detection module. Water insoluble DTPA analogues were dissolved in chloroform and as required watersoluble lanthanide complexes of DTPA analogues were dissolved in water. Although all of the new ligands and complexes prepared were air stable both in the solid state and solution, some of the ligands and complexes were found to be hygroscopic, when le in the open atmosphere for prolonged periods of time. Each sample was allowed to acclimatise to the desired temperature for 15 minutes prior to data collection. The reproducibility in T 1 measurements was within AE1%.
diacetate (1) . 36 The procedure as reported by Choi et al. 36 was used, except for slight modications. To tert-butyl bromoacetate (17.02 ml, 116 mmol) dissolved in DMF (30 ml), potassium carbonate (12.51 g, 90 mmol) was added. The reaction mixture was cooled down to 0 C and ethanolamine (2.98 ml, 49.4 mmol) added dropwise for 5 min. The reaction mixture was stirred at 0 C for 30 min and then allowed to stir overnight at room temperature. Aer an addition of concentrated NaHCO 3 (100 ml) and diethyl ether (150 ml), the organic layer was separated and washed with concentrated NaHCO 3 (50 ml) and subsequently with brine (200 ml). The solvent was removed under reduced pressure to yield the product as pale yellow solid. Yield 14.2 g, 42%; characterisation data was similar to that previously reported.
36
Synthesis of di-tert-butyl 2,2 0 -((2-bromoethyl)azanediyl) diacetate (2). 38 PPh 3 (4.34 g, 16.55 mmol) was dissolved in dichloromethane (25 ml), and NBS (2.99 g, 16.80 mmol) was added portion wise. The mixture was allowed to stir at 0 C (until the colour of the solution changes from yellow to light brown). The mixture was added to a dichloromethane (25 ml) solution of 1 (6.00 g, 20.74 mmol), dropwise at 0 C. The reaction mixture was allowed to stir overnight. The solvent was removed and to the crude product was added diethyl ether (30 ml). The sticky solid was triturated and ltered. The ltrate was evaporated and the crude product was ash chromatographed (hexane : diethyl ether, 5 : 1). The product was obtained as a colourless oil. Yield 2.0 g, 28%; 1 H NMR (400 MHz; 
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HCl (10 ml) was added and the reaction mixture was reuxed for 2 h. Aer 2 h, the solvent was removed in vacuo. 
Results and discussion
General synthesis
Ligand design and synthesis of DTPA analogues Symmetric ligand, L 1 (a) Synthesis of 2. The synthesis of 2 following the reported procedure gave low yields in our hands. However a small modication to the procedure allowed us to synthesise 2 in improved yield and purity. The phosphonium bromide was rst prepared by the portionwise addition of NBS to the dissolved solution of triphenyl phosphine in dichloromethane (successful preparation of the phosphonium bromide is indicated by the formation of sticky, semi solid-triphenylphosphine oxide).
44
The prepared phosphonium bromide was then added dropwise to the solution of 1 in dichloromethane. The rest of the procedure was followed as reported by Anelli et al.
38
(b) Alkylation of 3. Initially, compound 3 was added together with bromide 2 in the stoichiometric ratio of 1 : 2 in anhydrous DMF (Fig. 3) . The reaction mixture was heated to 65 C and allowed to reux for 48 h. Purication by thin layer chromatography (TLC) was carried out with 5% methanol/ dichloromethane used as the eluent. The puried protected form of the ligand thus obtained, subsequently underwent deprotection by reuxing the protected ligand in 2 M HCl for two hours according to the procedure reported by Vogt et al.
30
The ligand L 1 was isolated in good yield (90%).
Asymmetric ligand, L 2 . Triethylenetetramine (TRIEN) was reacted with 1,8-naphthalic anhydride to produce the new ligand 5. The 1 H NMR spectrum of the crude mixture conrmed the reaction had occurred with a signicant change to the aliphatic protons consistent with a lowering of the symmetry of the TRIEN core. The alkylation of this product was carried out using the same conditions as for the symmetric ligand, using stoichiometric amounts of alkylation agent (Fig. 4) . With resulting low yields, a 1 : 5 molar ratio was used to try to improve the amount of product and its purity, however 1 H NMR still indicated an the excess of compound 5. The reaction time was varied from 2 to 7 days, with little effect on the yield. Similarly, increasing the reaction temperature did not appreciably improve the yield. Purication of the reaction mixture was carried out by chromatography (95 : 5 dichloromethane/methanol) giving a yield of <20% isolated product. Each compound gave a spectrum consistent with the proposed structure. Chemical shis were assigned by comparison to previously publish data.
15,35,45
In 4, the four equivalent pendant carboxylate CH 2 -protons appear as a broad singlet at 2.85 ppm indicating a strong upeld shi due to alkylation and the CH 2 -protons are subsequently shied to 3.40 ppm upon deprotection, in L 1 . Curiously, a similar singlet was visible in the protected form of L 2 (6) at 3.40 ppm, suggesting a less intensive inductive effect by adjacent t-butyl groups. IR spectroscopy. The infrared spectrum of both L 1 and L 2 exhibited strong absorption bands in the region of 3300-3400 cm À1 and 1650 cm À1 , corresponding to NH and CO stretching vibrations, respectively (Table 1) . Upon complexation with gadolinium, the CO stretching vibrations of the amide Mass spectrometry. The molecular ions for the Gd(III) complexes of both L 1 and L 2 were visible in the mass spectra of these respective ligands. In the ESI mass spectra acquired in the negative mode indicated molecular ion peak of L 1 at 557.16.
However, the most intense peak for L 2 at 559.20 was found in the positive mode.
Evaluation of DTPA analogues
Both centrally and terminally substituted DTPA analogues have been exploited for their use in MRI applications. 47 As of today, most of the DTPA analogues tested and recognized as contrast agents belong to the terminally-substituted category, 48 but investigations related to direct substitution of a chromophoric moiety in the central nitrogen, remains scarce.
13,44,46
Similarly, terminally substituted and C-substituted (on ethylenic carbon) analogues comprise the majority of DTPA analogues (including the commercially available contrast agents, namely Eovist® and Multihance®). Further, DTPA analogues have been investigated for their usage in dissociation enhanced uoroimmunoassay (DELFIA).
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Fluorescence on binding with lanthanides
In the following experiments we have not concerned ourselves with the lanthanide phosphorescence spectrum. Instead, we are interested by changes in the organic uorescence spectrum on lanthanide binding. Primarily, we wish to show that the organic lumophore is not totally quenched upon lanthanide binding and any shi in the spectrum is small.
The emission proles of the protected form of the symmetric ligand, 4, compared to its deprotected form, L 1 , exhibited only slight differences, with only a slight red shi occurring in the excitation wavelength. The formation of the gadolinium complex, conrmed through the use of xylenol orange, results in little change to the luminescence spectrum, with no difference noted in the excitation wavelength and no change observed in the emission spectrum, compared to L 1 (Table 3 and Fig. 5) . Similarly, the formation of the gadolinium complex of L 2 did not result in a signicant quenching of the luminescence signal of the free ligand (Fig. 6 ), nor did it shi the excitation and emission wavelengths to a signicant degree. Clearly, the luminescence spectroscopy indicates that it may be possible to utilize the gadolinium complexes of L 1 and L 2 as luminescent probes, though their efficiency in such an application remains to be determined. . Reproducibility of the results was ensured by repeating the whole synthesis and repeating the measurements under the same conditions. Long term reproducibility of relaxivity of the same sample, under identical experimental conditions over an extended period of time (4 months) was also established. Long term stability of the same sample in solution was also corroborated by testing with xylenol orange indicator indicating the absence of free Gd(III) in the sample. The relaxivity of a 1 mM concentration solution of the complex is high compared to other standard DTPA based complexes (8.10 AE 0.21 mM À1 s À1 at 30 MHz, 25 C). The comparable relaxivity data is given in Table 2 .
The enhancement relaxivity of water protons results from dipolar interaction of the electron magnetic moment of the paramagnetic metal ion with that of the nuclear magnetic moment of solvent nuclei. This interaction comprises contributions from water molecules that belong to the inner, outer and secondary coordination spheres. It has been reported, that for low molecular weight Gd(III) based mono aqua hydrophilic complexes, the inner-sphere and outer-sphere contributions are comparable, giving rise to relaxivity values which lie in the range of 4-5 mM À1 s À1 at 25 C and 20 MHz, 1 while the contribution from secondary-sphere water molecules has not been as extensively studied.
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However, the observed relaxivity was very much on the higher side for Gd(III)-L 1 (8.65 mM À1 s À1 ) could be related to the concentration of the contrast agent by the following equation.
where R 1W represents the relaxivity of pure water (0.55 mM À1 s À1 in 30 MHz, 25 C). Therefore the true relaxivity of Gd(III)-L 1 is 8.10 mM À1 s À1 , which is still relatively higher than the relaxivity of the commercial contrast agent, 'Eovist'. As per the equation below, relaxivity is highly dependent on the number of water molecules bound to the metal centre (q) and their rate of exchange with the bulk water (s M ).
(1/T 1 ) ¼ qP m [1/(T 1m + s M )]
where 1/T 1 is the longitudinal relaxation rate and P m is the mole fraction of water coordinated to the metal centre. All commercial contrast agents possess q ¼ 1, which results in comparatively low relaxivity. Gd(III) complexes possessing high relaxivity with high q values (q ¼ 2) have been reported in the past for acylic aminocarboxylate compounds as well. 57 However, such an approach is problematic due to decreased complex stability and hence increased agent toxicity. In addition, higher q values may lead to the ready formation of ternary complexes in biological media and ultimately lead to lower relaxivity in vivo.
Conclusions
Two new DTPA analogues have been synthesized. A chromophore bearing, central nitrogen substituted, DTPA analogue has been synthesized distinguishing these new ligands from commercial contrast agents and incorporating the naphthalimide moiety into the DTPA backbone. The Gd(III) complexes exhibit ligand-based luminescence and Gd-L 1 has a relatively high relaxivity. Further investigations are necessary to determine if these reagents are toxic and the relaxivity is maintained in vivo.
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